{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:54Z","timestamp":1788866934464,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eprac.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:18:44Z","timestamp":1775099924000},"page":"1258-1265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Changing Landscape of Pediatric Endocrinology in Cystic Fibrosis: Insights From the Post-CFTR Modulator Era"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-9871","authenticated-orcid":false,"given":"Kevin","family":"Scully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Apsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Larson","family":"Ode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.02.019_bib1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.02.019_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2026.02.019_bib3","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/ppul.23894","article-title":"Bone mineral density is related to lung function outcomes in young people with cystic fibrosis-A retrospective study","volume":"52","author":"Smith","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib5","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","article-title":"Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications","volume":"18","author":"Anabtawi","year":"2019","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jcf.2015.04.005","article-title":"Cystic fibrosis-related bone disease in children: examination of peripheral quantitative computed tomography (pQCT) data","volume":"14","author":"Brookes","year":"2015","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420188251328210","article-title":"Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment","volume":"16","author":"Cobb","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/thx.2006.075887","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone","volume":"62","author":"Shead","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.eprac.2026.02.019_bib9","first-page":"1","article-title":"Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease","volume":"e80098","author":"Stalvey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2026.02.019_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/09031936.04.00050204","article-title":"Reduced bone density in cystic fibrosis: deltaF508 mutation is an independent risk factor","volume":"25","author":"King","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eprac.2026.02.019_bib11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.ajpath.2012.01.039","article-title":"The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation","volume":"180","author":"Le Henaff","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eprac.2026.02.019_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcf.2010.05.001","article-title":"Osteopenia in Cftr-deltaF508 mice","volume":"9","author":"Paradis","year":"2010","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib13","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)\/RANK ligand\/osteoprotegerin: clinical implications","volume":"92","author":"Vega","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcf.2022.08.011","article-title":"Evaluation of an association between RANKL and OPG with bone disease in people with cystic fibrosis","volume":"22","author":"Abid","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib15","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1210\/jc.2014-1982","article-title":"Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis","volume":"99","author":"Putman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"10 Suppl","key":"10.1016\/j.eprac.2026.02.019_bib17","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-3476(88)80268-3","article-title":"Osteoporosis in cystic fibrosis","volume":"113","author":"Gibbens","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.eprac.2026.02.019_bib20","first-page":"197","article-title":"Low serum bone gamma-carboxyglutamic acid protein concentrations in patients with cystic fibrosis: correlation with hormonal parameters and bone mineral density","volume":"39","author":"De Schepper","year":"1993","journal-title":"Horm Res"},{"key":"10.1016\/j.eprac.2026.02.019_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(96)70424-9","article-title":"Bone density in children and adolescents with cystic fibrosis","volume":"128","author":"Henderson","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.eprac.2026.02.019_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1164\/rccm.200606-776OC","article-title":"Low bone mineral density in young children with cystic fibrosis","volume":"175","author":"Sermet-Gaudelus","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib23","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib24","first-page":"1","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","volume":"CD002010","author":"Jeffery","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2026.02.019_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2026.02.019_bib26","doi-asserted-by":"crossref","first-page":"E1248","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"Putman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ppul.26314","article-title":"The impact of CFTR modulators on bone health","volume":"58","author":"Clarke","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib29","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib30","first-page":"1","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor effect on bone density and body composition: a retrospective analysis","volume":"e71280","author":"Trost","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib32","doi-asserted-by":"crossref","first-page":"S416a","DOI":"10.1016\/S1569-1993(25)02312-4","article-title":"696 bone mineral density in young children with cystic fibrosis pre- and post-elexacaftor\/tezacaftor\/ivacaftor \u2013 the BEGIN study","volume":"24","author":"Bezerra","year":"2025","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eprac.2026.02.019_bib34","first-page":"240","article-title":"Behavioral intervention to improve calorie intake of children with cystic fibrosis: treatment versus wait list control","volume":"22","author":"Stark","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.eprac.2026.02.019_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2011.10.006","article-title":"Qualitative analysis of parent experiences with achieving cystic fibrosis nutrition recommendations","volume":"11","author":"Filigno","year":"2012","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jpeds.2005.06.003","article-title":"Overweight and obesity in deltaF508 homozygous cystic fibrosis","volume":"147","author":"Kastner-Cole","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.eprac.2026.02.019_bib37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.eprac.2026.02.019_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.02.019_bib39","series-title":"s","article-title":"Maintaining healthy weight with cystic fibrosi","year":"2020"},{"key":"10.1016\/j.eprac.2026.02.019_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/nu16183103","article-title":"Is obesity a problem in new cystic fibrosis treatments?","volume":"16","author":"Sol\u00eds-Garc\u00eda","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2026.02.019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2023.112091","article-title":"Dietary intake, weight status, pulmonary function, and metabolic profile in children with cystic fibrosis with or without pancreatic sufficiency","volume":"114","author":"Papachristou","year":"2023","journal-title":"Nutrition"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.02.019_bib42","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.02.019_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eprac.2026.02.019_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2021.05.002","article-title":"Overweight and obesity in adults with cystic fibrosis: an Italian multicenter cohort study","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.02.019_bib45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MCP.0000000000001013","article-title":"Evolving nutritional needs, obesity, and overweight status in cystic fibrosis","volume":"29","author":"Szentpetery","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib46","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.eprac.2026.02.019_bib47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.healun.2006.03.011","article-title":"International Guidelines for the selection of lung transplant candidates: 2006 Update-A consensus report from the pulmonary scientific council of the international society for heart and lung transplantation","volume":"25","author":"Orens","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eprac.2026.02.019_bib48","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.019_bib49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clnu.2025.09.008","article-title":"Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis","volume":"54","author":"Bader-Larsen","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.eprac.2026.02.019_bib50","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"L\u00f3pez C\u00e1rdenes","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib51","first-page":"1","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"3293","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.019_bib52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.02.019_bib53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MCP.0000000000000917","article-title":"Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era","volume":"28","author":"Wilschanski","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.eprac.2026.02.019_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5868-2-9","article-title":"Psychosocial predictors of eating habits among adults in their mid-30s: the Oslo youth study follow-up 1991-1999","volume":"2","author":"Kvaavik","year":"2005","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.eprac.2026.02.019_bib56","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jand.2020.03.016","article-title":"Dietary macronutrient distribution and nutrition outcomes in persons with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"McDonald","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.eprac.2026.02.019_bib57","series-title":"2023 patient registry annual data report","year":"2023"},{"key":"10.1016\/j.eprac.2026.02.019_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081545","article-title":"Diabetes in cystic fibrosis: multicenter screening results based on current guidelines","volume":"8","author":"Scheuing","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.019_bib59","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.019_bib60","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2026.02.019_bib61","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.019_bib62","first-page":"100","article-title":"Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes","volume":"1","author":"Millington","year":"2014","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.019_bib63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","article-title":"The impact of cystic fibrosis-related diabetes on health-related quality of life","volume":"18","author":"Kwong","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.019_bib64","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.019_bib65","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2026.02.019_bib66","first-page":"1","article-title":"Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review","volume":"1623654","author":"Giordano","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2026.02.019_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2026.02.019_bib68","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation \u2013 the Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of Ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.019_bib71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","author":"Thomassen","year":"2018","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.019_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/Ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cystic Fibrosis"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.019_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.019_bib75","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1164\/rccm.202411-2312OC","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on glucose tolerance and abnormal glucose metabolism: a phase 3b, open-label clinical trial","volume":"211","author":"Durieu","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2022.852551","article-title":"Short-Term effects of Elexacaftor\/Tezacaftor\/Ivacaftor combination on glucose tolerance in young people with cystic Fibrosis-An observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.eprac.2026.02.019_bib77","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.eprac.2026.02.019_bib78","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.019_bib79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of \u03b2-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","volume":"109","author":"Flatt","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib80","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"110","author":"Chan","year":"2025","journal-title":"PROMISE-ENDO. J Clin Endocrinol Metab."},{"key":"10.1016\/j.eprac.2026.02.019_bib81","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1210\/clinem\/dgaf099","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on glucose tolerance in adolescents with cystic fibrosis","volume":"110","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.019_bib82","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.02.019_bib83","first-page":"1","article-title":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","volume":"111839","author":"Aguilera Garc\u00eda","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.02.019_bib84","first-page":"1309","article-title":"One-Year effect of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study","volume":"14","author":"Bassi","year":"2024","journal-title":"Life (Basel)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:53:27Z","timestamp":1785837207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1530891X26009237"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.019","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Landscape of Pediatric Endocrinology in Cystic Fibrosis: Insights From the Post-CFTR Modulator Era","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}